Patent application number | Description | Published |
20090010819 | VERSATILE FLOW PATH - A flow path comprising a reaction cavity in which there is a solid phase to which an affinity reactant I1 has been immobilized by the use of an immobilizing pair of reactive structures that comprises a) a plurality of functional equal structures RSsp on the solid phase, and b) a structure RSari on affinity reactant I1, where RSsp and RSari are mutually reactive with each other to the formation of a link structure that immobilizes affinity reactant I1 to the solid phase. The characteristic feature is that the solid phase comprises a plurality of structures that derive from RSsp but do not immobilize affinity reactant I1 to the solid phase. | 01-08-2009 |
20090215196 | Sequential Method - A method for determination of an analyte in an original liquid sample by performing an inhibition affinity assay in a microchannel structure of a microfluidic device. The main characteristic feature is the steps of: (i) providing the microfluidic device in a form where the microchannel structure comprises a reaction microcavity which a) an inlet end, and b) contains a solid phase with binding sites (BS) for an analyte or an analyte-related entity, (ii) providing a liquid sample (1) containing the analyte or the analyte-related entity within the microchannel structure at the inlet end of the reaction microcavity, and flowing sample (1) through the reaction microcavity under conditions such that the analyte or the analyte-related entity is captured by BS leaving a portion of BS unoccupied (free BS), (iii) providing a liquid sample (2) which contains an analytically detectable analogue of the analyte or of the analyte-related entity, and flowing sample (2) through said reaction microcavity to capture the analogue by free BS, and (iv) measuring the amount of analyte analogue captured in step (iii) and relating this amount to the amount of analyte in an original sample. | 08-27-2009 |
20110116972 | MICROFLUIDIC ASSAYS AND MICROFLUIDIC DEVICES - The invention is a method for determining in the amount of an analyte (An) in a sample. The method comprises competitive immunoassays and enzymatic assays in which a soluble product (immune complex and enzymatic product, respectively) is formed. The product is subsequently measured in a measuring zone of a microchannel structure of a microfluidic device. | 05-19-2011 |
20120308572 | Protofibril-Binding Antibodies and Their Use in Therapeutic and Diagnostic Methods for Parkinson's Disease, Dementia with Lewy Bodies and Other Alpha-Synucleinopathies - Antibodies and fragments thereof have high affinity for human α-synuclein protofibrils and low binding of α-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting α-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with α-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with α-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with α-synuclein pathology, and in methods for reducing or inhibiting α-synuclein aggregation by administration of such an antibody or fragment. | 12-06-2012 |
20130309251 | Protofibril-Binding Antibodies And Their Use In Therapeutic And Diagnostic Methods For Parkinson's Disease, Dementia With Lewy Bodies And Other Alpha-Synucleinopathies - Antibodies and fragments thereof have high affinity for human α-synuclein protofibrils and low binding of α-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting α-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with α-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with α-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with α-synuclein pathology, and in methods for reducing or inhibiting α-synuclein aggregation by administration of such an antibody or fragment. | 11-21-2013 |
20140363447 | Protofibril-Binding Antibodies And Their Use In Therapeutic And Diagnostic Methods For Parkinson's Disease, Dementia With Lewy Bodies And Other Alpha-Synucleinopathies - Antibodies and fragments thereof have high affinity for human α-synuclein protofibrils and low binding of α-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting α-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with α-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with α-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with α-synuclein pathology, and in methods for reducing or inhibiting α-synuclein aggregation by administration of such an antibody or fragment. | 12-11-2014 |
20150139900 | Protofibril-Binding Antibodies And Their Use In Therapeutic And Diagnostic Methods For Parkinson's Disease, Dementia With Lewy Bodies And Other Alpha-Synucleinopathies - An in vivo method for detecting α-synuclein protofibrils in human tissue comprises administering an antibody or fragment thereof to a human, wherein the antibody or fragment thereof is labelled with a detectable label, and detecting a complex formed between the antibody or fragment thereof and α-synuclein protofibrils in the human tissue. The antibody or fragment thereof has high affinity for human α-synuclein protofibrils and low binding of α-synuclein monomers and has a combination of three specified variable heavy (VH) CDR sequences and three specified variable light (VL) CDR sequences. | 05-21-2015 |